Filter posts

Wall Street Journal: Patients Deserve Better

In case you missed it, The Wall Street Journal published my Letter to the Editor …

Emerging Themes in Personalized Medicine

The adoption of Personalized Medicine is being driven by the omnipresence of Next-Generation Sequencing (NGS), …

WSJ Article Cherry Picks Cost, Ignores Value of Medicines

Today’s Wall Street Journal story, “Price Increases Drive Drug Firms’ Revenue” reaffirms that old chestnut, …

Biopharma Companies Fight Tropical Diseases to Improve Global Health

Neglected tropical diseases (NTDs) are a group of devastating viral, bacterial, and parasitic diseases that …

Dr. Scott Gottlieb: A Clintonian Misdirection on Drug Prices

Today’s Wall Street Journal contains an excellent op-ed by Dr. Scott Gottlieb, a physician and …

Discover Trends and Investment Opportunities at the BIO Investor Forum

The 2015 BIO Investor Forum in San Francisco is shaping up to be a must-attend event …

Wall Street Journal: The Assault on Drug Innovation

Today, the Wall Street Journal published an editorial commenting on yesterday’s proposed plan by Secretary Hillary Clinton’s …

BIO Statement on Patient Access to Medicines

“As a general policy, BIO does not comment on matters related to individual company products …

Reality Check for AHIP: Competition Driving Down Costs for Hepatitis C Meds

Yesterday at a House Judiciary Committee hearing on competition in the healthcare marketplace, AHIP Executive Vice …

BIO Statement: Institute for Clinical and Economic Review Framework

This week, the Institute for Clinical and Economic Review (ICER) released its Value Assessment Framework. …